Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting

Breast Cancer Research

Volumn 11, Issue 6, 2009, Pages

  Habel, Laurel A ^a   Achacoso, Ninah S ^a   Haque, Reina ^b   Nekhlyudov, Larissa ^c,d   Fletcher, Suzanne W ^c   Schnitt, Stuart J ^c   Collins, Laura C ^c   Geiger, Ann M ^e   Puligandla, Balaram ^f   Acton, Luana ^a   Quesenberry Jr, Charles P ^a  

^a DIVISION OF RESEARCH   (United States)

^b Kaiser Permanente Southern California   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; COMMUNITY CARE; CONTROLLED STUDY; FEMALE; HEALTH INSURANCE; HEALTH MAINTENANCE ORGANIZATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL RECORD REVIEW; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; RETROSPECTIVE STUDY; THERAPY EFFECT; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; CARCINOMA IN SITU; CASE CONTROL STUDY; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; TAMOXIFEN; TREATMENT OUTCOME;

EID: 77954605793     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2453     Document Type: Article

References (41)

1. Li CI, Malone KE, Saltzman BS, Daling JR. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. Cancer 2006, 106:2104-2112. 10.1002/cncr.21864, 16604564.
2. Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 1996, 275:913-918. 10.1001/jama.275.12.913, 8598618.
3. Ernster VL, Ballard-Barbash R, Barlow WE, Zheng Y, Weaver DL, Cutter G, Yankaskas BC, Rosenberg R, Carney PA, Kerlikowske K, Taplin SH, Urban N, Geller BM. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2002, 94:1546-1554.
4. Schnitt SJ, Silen W, Sadowsky NL, Connolly JL, Harris JR. Ductal carcinoma in situ (intraductal carcinoma) of the breast. N Engl J Med 1988, 318:898-903.
5. American Cancer Society Cancer Facts & Figures 2008. 2008, Atlanta: American Cancer Society, American Cancer Society.
6. Fisher B, Bauer M, Margolese R, Poisson R, Pilch Y, Redmond C, Fisher E, Wolmark N, Deutsch M, Montague E, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985, 312:665-673.
7. Fisher B, Redmond C, Poisson R, Margolese R, Wolmark N, Wickerham L, Fisher E, Deutsch M, Caplan R, Pilch Y, et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989, 320:822-828.
8. Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 2004, 96:443-448.
9. Joslyn SA. Ductal carcinoma in situ: trends in geographic, temporal, and demographic patterns of care and survival. Breast J 2006, 12:20-27. 10.1111/j.1075-122X.2006.00182.x, 16409583.
10. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, Wolff AC, . NCCN Breast Cancer Clinical Practice Guidelines Panel Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2009, 7:122-192. NCCN Breast Cancer Clinical Practice Guidelines Panel.
11. Schwartz GF, Solin LJ, Olivotto IA, Ernster VL, Pressman PI. Consensus Conference on the Treatment of In Situ Ductal Carcinoma of the Breast, April 22-25, 1999. Cancer 2000, 88:946-954. 10.1002/(SICI)1097-0142(20000215)88:4<946::AID-CNCR26>3.0.CO;2-5, 10679665.
12. National Cancer Institute. Ductal Carcinoma in Situ (DCIS) Research Resources. Clinical Trials , http://appliedresearch.cancer.gov/dcis/projects/trials.html
13. U.S. Food and Drug Administration Drugs@FDA. FDA Approved Drug Products. U.S. Food and Drug Administration., http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm
14. Yen TW, Kuerer HM, Ottesen RA, Rouse L, Niland JC, Edge SB, Theriault RL, Weeks JC. Impact of randomized clinical trial results in the national comprehensive cancer network on the use of tamoxifen after breast surgery for ductal carcinoma in situ. J Clin Oncol 2007, 25:3251-3258. 10.1200/JCO.2006.10.2699, 17577019.
15. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol 2001, 28:400-418. 10.1016/S0093-7754(01)90133-2, 11498833.
16. Julien JP, Bijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, Avril A, Sylvester R, Mignolet F, Bartelink H, Van Dongen JA. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000, 355:528-533. 10.1016/S0140-6736(99)06341-2, 10683002.
17. Emdin SO, Granstrand B, Ringberg A, Sandelin K, Arnesson LG, Nordgren H, Anderson H, Garmo H, Holmberg L, Wallgren A, . Swedish Breast Cancer Group SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol 2006, 45:536-543. 10.1080/02841860600681569, 16864166, Swedish Breast Cancer Group.
18. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG, Kardinal CG, Kavanah MT, Fehrenbacher L, Oishi RH. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999, 353:1993-2000. 10.1016/S0140-6736(99)05036-9, 10376613.
19. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003, 362:95-102. 10.1016/S0140-6736(03)13859-7, 12867108.
20. Lagios MD, Margolin FR, Westdahl PR, Rose MR. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989, 63:618-624. 10.1002/1097-0142(19890215)63:4<618::AID-CNCR2820630403>3.0.CO;2-J, 2536582.
21. Silverstein MJ, Lagios MD. Use of predictors of recurrence to plan therapy for DCIS of the breast. Oncology (Williston Park) 1997, 11:393-410.
22. Kerlikowske K, Molinaro A, Cha I, Ljung BM, Ernster VL, Stewart K, Chew K, Moore DH, Waldman F. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst 2003, 95:1692-1702.
23. Lagios MD. Duct carcinoma in situ. Pathology and treatment. Surg Clin North Am 1990, 70:853-871.
24. Hetelekidis S, Collins L, Silver B, Manola J, Gelman R, Cooper A, Lester S, Lyons JA, Harris JR, Schnitt SJ. Predictors of local recurrence following excision alone for ductal carcinoma in situ. Cancer 1999, 85:427-431. 10.1002/(SICI)1097-0142(19990115)85:2<427::AID-CNCR21>3.0.CO;2-8, 10023711.
25. Fisher ER, Costantino J, Fisher B, Palekar AS, Redmond C, Mamounas E. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators. Cancer 1995, 75:1310-1319. 10.1002/1097-0142(19950315)75:6<1310::AID-CNCR2820750613>3.0.CO;2-G, 7882281.
26. Silverstein MJ, Lagios MD, Groshen S, Waisman JR, Lewinsky BS, Martino S, Gamagami P, Colburn WJ. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999, 340:1455-1461. 10.1056/NEJM199905133401902, 10320383.
27. Rothman K, Greenland S. Case- control Studies. Modern Epidemiology 1998, 93-114. Philadelphia: Lippincott-Raven, Rothman KJ, Greenland S.
28. Kalbfleisch J, Prentice R. The Statistical Analysis of Failure Time Data. 1980, 167-168. Hoboken, NJ: Wiley.
29. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data?. Stat Med 1993, 12:737-751. 10.1002/sim.4780120803, 8516591.
30. Prentice RL, Kalbfleisch JD, Peterson AV, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics 1978, 34:541-554. 10.2307/2530374, 373811.
31. Bijker N, Peterse JL, Duchateau L, Julien JP, Fentiman IS, Duval C, Di Palma S, Simony-Lafontaine J, de Mascarel I, Vijver MJ. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 2001, 19:2263-2271.
32. Dunne C, Burke JP, Morrow M, Kell MR. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol 2009, 27:1615-1620. 10.1200/JCO.2008.17.5182, 19255332.
33. Fisher ER, Dignam J, Tan-Chiu E, Costantino J, Fisher B, Paik S, Wolmark N. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer 1999, 86:429-438. 10.1002/(SICI)1097-0142(19990801)86:3<429::AID-CNCR11>3.0.CO;2-Y, 10430251.
34. Li CI, Daling JR, Malone KE. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol Biomarkers Prev 2005, 14:1008-1011. 10.1158/1055-9965.EPI-04-0849, 15824180.
35. , Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, Gennaro M, Rouanet P, Avril A, Fentiman IS, Bartelink H, Rutgers EJ. EORTC Breast Cancer Cooperative Group, EORTC Radiotherapy Group Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006, 24:3381-3387. 10.1200/JCO.2006.06.1366, 16801628, EORTC Breast Cancer Cooperative Group, EORTC Radiotherapy Group.
36. Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, Fisher ER, Wickerham DL, Deutsch M, Margolese R, Dimitrov N, Kavanah M. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998, 16:441-452.
37. Habel LA, Daling JR, Newcomb PA, Self SG, Porter PL, Stanford JL, Seidel K, Weiss NS. Risk of recurrence after ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 1998, 7:689-696.
38. Bijker N, Peterse JL, Fentiman IS, Julien JP, Hart AA, Avril A, Cataliotti L, Rutgers EJ. Effects of patient selection on the applicability of results from a randomised clinical trial (EORTC 10853) investigating breast-conserving therapy for DCIS. Br J Cancer 2002, 87:615-620. 10.1038/sj.bjc.6600514, 2364244, 12237770.
39. Wickerham DL. Ductal carcinoma-in-situ. J Clin Oncol 2001, 19:98S-100S.
40. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994, 86:527-537. 10.1093/jnci/86.7.527, 8133536.
41. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90:1371-1388. 10.1093/jnci/90.18.1371, 9747868.